ACM
AEGR

Americafirst Capital Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Americafirst Capital Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-83,580
Closed -$844M – 240
2015
Q4 		$844M Buy
83,580
+38,097
+84% +$459K 0.51% 64
2015
Q3 		$619M Buy
45,483
+7,181
+19% +$128K 0.36% 99
2015
Q2 		$727K Buy
+38,302
New +$829K 0.39% 109

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Americafirst Capital Management's AEGR Position: Q1 2016 in Review

Americafirst Capital Management sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 83,580 shares — an estimated $844M sold.

Americafirst Capital Management first reported a position in AEGR in Q2 2015 and held it in 3 quarters. The position peaked at $844M in Q4 2015. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • Americafirst Capital Management reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Americafirst Capital Management sold 83,580 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $844M.
  • Americafirst Capital Management first reported a position in Aegerion Pharmaceuticals in Q2 2015 and held it in 3 quarters.
  • Americafirst Capital Management's Aegerion Pharmaceuticals position peaked at $844M in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on Americafirst Capital Management's 13F filing for Q1 2016, filed 16 May 2016.